Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Inactivation of the Glucose-Dependent Insulinotropic Polypeptide Receptor Improves Outcomes following Experimental Myocardial Infarction
John R. Ussher, Jonathan E. Campbell, Erin E. Mulvihill, et al.
Cell Metabolism (2017) Vol. 27, Iss. 2, pp. 450-460.e6
Open Access | Times Cited: 76

Showing 1-25 of 76 citing articles:

Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
Laurie L. Baggio, Daniel J. Drucker
Molecular Metabolism (2020) Vol. 46, pp. 101090-101090
Open Access | Times Cited: 220
The evolving story of incretins (GIP and GLP‐1) in metabolic and cardiovascular disease: A pathophysiological update
Michael A. Nauck, Daniel R. Quast, Jakob Wefers, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. S3, pp. 5-29
Closed Access | Times Cited: 219
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
John R. Ussher, Daniel J. Drucker
Nature Reviews Cardiology (2023) Vol. 20, Iss. 7, pp. 463-474
Closed Access | Times Cited: 215
GLP-1 Receptor Expression Within the Human Heart
Laurie L. Baggio, Bernardo Yusta, Erin E. Mulvihill, et al.
Endocrinology (2018) Vol. 159, Iss. 4, pp. 1570-1584
Open Access | Times Cited: 213
The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling
Qian Zhang, Tenagne D. Challa, Robert Augustin, et al.
Cell Metabolism (2021) Vol. 33, Iss. 4, pp. 833-844.e5
Open Access | Times Cited: 192
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
Michael A. Nauck, David A. D‘Alessio
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 175
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Rola Hammoud, Daniel J. Drucker
Nature Reviews Endocrinology (2022) Vol. 19, Iss. 4, pp. 201-216
Closed Access | Times Cited: 127
The expanding incretin universe: from basic biology to clinical translation
Daniel J. Drucker, Jens J. Holst
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1765-1779
Open Access | Times Cited: 117
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics
Stephen J. Nicholls, Deepak L. Bhatt, John B. Buse, et al.
American Heart Journal (2023) Vol. 267, pp. 1-11
Open Access | Times Cited: 84
Glucose-dependent insulinotropic polypeptide (GIP)
Timo D. Müller, Alice E. Adriaenssens, Bo Ahrén, et al.
Molecular Metabolism (2025) Vol. 95, pp. 102118-102118
Open Access | Times Cited: 2
Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
Megan E. Capozzi, Richard D. DiMarchi, Matthias H. Tschöp, et al.
Endocrine Reviews (2018) Vol. 39, Iss. 5, pp. 719-738
Open Access | Times Cited: 127
The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes
Jonathan M. Wilson, Amir Nikooienejad, Deborah Robins, et al.
Diabetes Obesity and Metabolism (2020) Vol. 22, Iss. 12, pp. 2451-2459
Open Access | Times Cited: 122
Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases
Christoffer Clemmensen, Brian Finan, Timo D. Müller, et al.
Nature Reviews Endocrinology (2018) Vol. 15, Iss. 2, pp. 90-104
Closed Access | Times Cited: 104
Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms
Jonathan E. Campbell
Molecular Metabolism (2020) Vol. 46, pp. 101139-101139
Open Access | Times Cited: 86
Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease—Current Evidence
Emir Muzurović, Špela Volčanšek, Karin Zibar, et al.
Journal of Cardiovascular Pharmacology and Therapeutics (2022) Vol. 27
Open Access | Times Cited: 51
GIPR Is Predominantly Localized to Nonadipocyte Cell Types Within White Adipose Tissue
Jonathan E. Campbell, Jacqueline L. Beaudry, Berit Svendsen, et al.
Diabetes (2022) Vol. 71, Iss. 5, pp. 1115-1127
Open Access | Times Cited: 42
Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice
Arkadiusz Liśkiewicz, Ahmed Khalil, Daniela Liśkiewicz, et al.
Nature Metabolism (2023) Vol. 5, Iss. 12, pp. 2075-2085
Open Access | Times Cited: 36
The importance of glucose‐dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide
Lærke S. Gasbjerg, Mette M. Rosenkilde, Juris J. Meier, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 11, pp. 3079-3092
Closed Access | Times Cited: 24
Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide
Fatemeh Taktaz, Rosaria Anna Fontanella, Lucia Scisciola, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 13
The role of GIP in α-cells and glucagon secretion
Kimberley El, Jonathan E. Campbell
Peptides (2019) Vol. 125, pp. 170213-170213
Open Access | Times Cited: 74
Glucose-Dependent Insulinotropic Polypeptide Receptor Therapies for the Treatment of Obesity, Do Agonists = Antagonists?
Elizabeth A. Killion, Shu-Chen Lu, Madeline Fort, et al.
Endocrine Reviews (2019) Vol. 41, Iss. 1, pp. 1-21
Open Access | Times Cited: 72
Tissue-specific regulation of p53 by PKM2 is redox dependent and provides a therapeutic target for anthracycline-induced cardiotoxicity
Bruno Saleme, Vikram Gurtu, Yongneng Zhang, et al.
Science Translational Medicine (2019) Vol. 11, Iss. 478
Closed Access | Times Cited: 58
The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: Implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD)
Sravan Thondam, Daniel J. Cuthbertson, John Wilding
Peptides (2019) Vol. 125, pp. 170208-170208
Closed Access | Times Cited: 55
The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction
Ali A. Rizvi, Manfredi Rizzo
Diabetes Metabolic Syndrome and Obesity (2022) Vol. Volume 15, pp. 1023-1030
Open Access | Times Cited: 37
Glucagon-like Peptide-1 receptor Tie2+ cells are essential for the cardioprotective actions of liraglutide in mice with experimental myocardial infarction
Brent A. McLean, Chi Kin Wong, M. Golam Kabir, et al.
Molecular Metabolism (2022) Vol. 66, pp. 101641-101641
Open Access | Times Cited: 35
Page 1 - Next Page

Scroll to top